Gilteritinib
- Generic Name
- Gilteritinib
- Brand Names
- Xospata
- Drug Type
- Small Molecule
- Chemical Formula
- C29H44N8O3
- CAS Number
- 1254053-43-4
- Unique Ingredient Identifier
- 66D92MGC8M
- Background
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritin...
- Indication
Gilteritinib is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia with an FLT3 mutation detected by an FDA-approved test. This indication was expanded for a companion diagnostic to include use with gilteritinib such as the LeukoStrat CDx FLT3 Mutation Assay.
...
- Associated Conditions
- Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
- Associated Therapies
- -
Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT06734585
Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2024-10-31
- Target Recruit Count
- 80
- Registration Number
- NCT06667973
The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation
- Conditions
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-20
- Target Recruit Count
- 36
- Registration Number
- NCT06561880
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 147
- Registration Number
- NCT06317649
- Locations
- 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06235801
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Gilteritinib for the Treatment of ALK NSCLC
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06225427
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
- Conditions
- Interventions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Children's Hospital of Soochow University
- Target Recruit Count
- 500
- Registration Number
- NCT06221683
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳XiangYa Hospital Central South University, Changsha, Hunan, China
🇨🇳Children's Hospital of Soochow University, Suzhou, Jiangsu, China
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
- Conditions
- Interventions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Uma Borate
- Target Recruit Count
- 30
- Registration Number
- NCT06222580
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 171
- Registration Number
- NCT06001788
- Locations
- 🇺🇸
The University of Kansas, Kansas City, Kansas, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Prisma Health, Greenville, South Carolina, United States
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT05955261
- Locations
- 🇺🇸
Rady Children's Hospital-San Diego, San Diego, California, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Cook Children's Medical Center, Fort Worth, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.